Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the transaction price of American Depositary Shares (ADSs) at $52.264 per ADS following the re-investment of dividends paid on July 11, 2013.
Material Changes
The filing details specific increases in ADS holdings for two individuals under the Deferred Annual Bonus Plan:
- Mrs D P Connelly: Acquired 32.509 ADSs (personal contribution) and 33.323 ADSs (company matching contribution).
- Mr W C Louv: Acquired 23.885 ADSs (personal contribution) and 24.417 ADSs (company matching contribution).
These transactions relate to deferred bonuses from 2010, 2011, and 2012 on a post-tax basis.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Investor Verification Points
- Verify the vesting schedule and measurement periods for the 2010, 2011, and 2012 deferred bonus awards mentioned.
- Confirm the total number of ADSs held by Mrs D P Connelly and Mr W C Louv post-transaction.
- Review the full terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan to understand the payout conditions for notional dividends.